Morgan Stanley Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target hoisted by Morgan Stanley from $234.00 to $317.00 in a report issued on Monday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

PODD has been the subject of a number of other research reports. Barclays boosted their target price on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. BTIG Research upped their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday. Canaccord Genuity Group upped their price target on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, UBS Group upped their price target on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Up 2.9 %

Shares of NASDAQ:PODD opened at $275.70 on Monday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet has a 1 year low of $156.00 and a 1 year high of $279.40. The stock has a market capitalization of $19.33 billion, a P/E ratio of 47.21, a PEG ratio of 5.00 and a beta of 1.22. The stock has a 50-day simple moving average of $233.46 and a 200-day simple moving average of $205.26.

Institutional Investors Weigh In On Insulet

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after buying an additional 169,506 shares during the last quarter. Baillie Gifford & Co. grew its stake in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after buying an additional 389,639 shares during the last quarter. Clearbridge Investments LLC grew its stake in Insulet by 6.0% during the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after buying an additional 75,526 shares during the last quarter. American Century Companies Inc. grew its stake in Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after buying an additional 139,246 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Insulet during the 2nd quarter worth $99,978,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.